Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Frankfurt | Healthcare | Pharmaceuticals | EUR 682.30B | 70.1x | 0.72 | EUR 756.10 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and | Xetra | Healthcare | Pharmaceuticals | EUR 668.74B | 69.8x | 0.72 | EUR 748.80 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | Vienna | Healthcare | Pharmaceuticals | EUR 668.16B | 69.8x | 0.72 | EUR 752.20 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson | Vienna | Healthcare | Pharmaceuticals | EUR 369.52B | 28.3x | -0.49 | EUR 151.90 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson | Frankfurt | Healthcare | Pharmaceuticals | EUR 365.96B | 28.3x | -0.49 | EUR 152.22 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson&Johnson | Xetra | Healthcare | Pharmaceuticals | EUR 363.87B | 28.3x | -0.49 | EUR 151.54 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie | Frankfurt | Healthcare | Pharmaceuticals | EUR 346.20B | 89.1x | -7.36 | EUR 194.86 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Vienna | Healthcare | Pharmaceuticals | EUR 344.07B | 88.7x | -7.36 | EUR 201.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk B | BATS Europe | Healthcare | Pharmaceuticals | EUR 317.90B | 23.5x | 1.13 | EUR 71.48 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Xetra | Healthcare | Pharmaceuticals | EUR 317.70B | 23.5x | 1.22 | EUR 71.19 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | Vienna | Healthcare | Pharmaceuticals | EUR 317.70B | 23.5x | 1.22 | EUR 71.22 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk A S | Frankfurt | Healthcare | Pharmaceuticals | EUR 317.70B | 23.5x | 1.22 | EUR 71.53 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | EUR 259.21B | 30.2x | -1.06 | EUR 308.31 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche | BATS Europe | Healthcare | Pharmaceuticals | EUR 259.21B | 30.2x | -1.06 | EUR 325.68 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding DRC | Frankfurt | Healthcare | Pharmaceuticals | EUR 259.10B | 30.2x | -1.06 | EUR 39.60 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Frankfurt | Healthcare | Pharmaceuticals | EUR 219.64B | 14.1x | 0 | EUR 86.70 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Xetra | Healthcare | Pharmaceuticals | EUR 219.23B | 14x | 0 | EUR 86.90 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck | Milan | Healthcare | Pharmaceuticals | EUR 219.21B | 14x | -8.78 | EUR 87.10 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co | Vienna | Healthcare | Pharmaceuticals | EUR 219.21B | 14x | 0 | EUR 88.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Vienna | Healthcare | Pharmaceuticals | EUR 211.25B | 32.8x | 1.9 | EUR 71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca PLC | Xetra | Healthcare | Pharmaceuticals | EUR 211.25B | 32.8x | 1.9 | EUR 136.55 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca DRC | Frankfurt | Healthcare | Pharmaceuticals | EUR 211.25B | 32.8x | 1.9 | EUR 70 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | Frankfurt | Healthcare | Pharmaceuticals | EUR 211.25B | 32.8x | 1.9 | EUR 137.15 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Astrazeneca | BATS Europe | Healthcare | Pharmaceuticals | EUR 211.22B | 32.8x | 1.9 | EUR 136 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | BATS Europe | Healthcare | Pharmaceuticals | EUR 210.85B | 32.8x | 1.87 | EUR 136.76 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis | BATS Europe | Healthcare | Pharmaceuticals | EUR 196.18B | 18.4x | -1.09 | EUR 99.51 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Frankfurt | Healthcare | Pharmaceuticals | EUR 158.18B | 42.1x | -1.08 | EUR 298.20 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Xetra | Healthcare | Pharmaceuticals | EUR 156.84B | 41.9x | -1.08 | EUR 293.25 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Vienna | Healthcare | Pharmaceuticals | EUR 156.77B | 41.9x | -1.08 | EUR 294.45 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Frankfurt | Healthcare | Pharmaceuticals | EUR 135.17B | 18.3x | 0.07 | EUR 23.78 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Xetra | Healthcare | Pharmaceuticals | EUR 134.61B | 18.4x | 0.07 | EUR 23.82 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer | Vienna | Healthcare | Pharmaceuticals | EUR 134.46B | 18.4x | 0.07 | EUR 24.42 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Milan | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.51 | EUR 107.24 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Vienna | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.51 | EUR 109.82 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | BATS Europe | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.55 | EUR 107.92 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi SA | Xetra | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.51 | EUR 107.46 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Frankfurt | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.51 | EUR 108 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sanofi | Paris | Healthcare | Pharmaceuticals | EUR 134.26B | 24.1x | 8.51 | EUR 107.44 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Gilead Sciences | Frankfurt | Healthcare | Pharmaceuticals | EUR 131.33B | 298.4x | -3.33 | EUR 104.80 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Milan | Healthcare | Pharmaceuticals | EUR 130.33B | 297.5x | -3.33 | EUR 105.54 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Vienna | Healthcare | Pharmaceuticals | EUR 130.33B | 297.5x | -3.33 | EUR 109.76 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Xetra | Healthcare | Pharmaceuticals | EUR 130.29B | 297.5x | -3.33 | EUR 104.92 | -4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Frankfurt | Healthcare | Pharmaceuticals | EUR 114.59B | -14x | 0.06 | EUR 56.33 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb | Vienna | Healthcare | Pharmaceuticals | EUR 114.40B | -14x | 0.06 | EUR 57.90 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers | Xetra | Healthcare | Pharmaceuticals | EUR 114.29B | -14x | 0.06 | EUR 56.53 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Xetra | Healthcare | Pharmaceuticals | EUR 73.28B | 24x | -0.5 | EUR 18.09 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | Frankfurt | Healthcare | Pharmaceuticals | EUR 73.28B | 24x | -0.5 | EUR 17.82 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK | Frankfurt | Healthcare | Pharmaceuticals | EUR 73.28B | 24x | -0.5 | EUR 37.20 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc | BATS Europe | Healthcare | Pharmaceuticals | EUR 73.26B | 24x | -0.5 | EUR 17.96 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Chugai Pharma | Frankfurt | Healthcare | Pharmaceuticals | EUR 69.43B | 28.8x | 1.56 | EUR 40.53 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |